Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 3/2013

01-09-2013 | Review Article

Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis

Authors: Driss Ait Ouakrim, Trevor Lockett, Alex Boussioutas, John L. Hopper, Mark A. Jenkins

Published in: Familial Cancer | Issue 3/2013

Login to get access

Abstract

We conducted a systematic review and a meta-analysis of observational studies to identify and summarise the level of colorectal cancer (CRC) screening participation for people at increased risk due to family history of the disease. Medline, Cinhal, Embase and PsychInfo databases were comprehensively searched between January 1995 and May 2012 to identify relevant articles. To be included, studies had to report on screening for people who had at least one first-degree relative with CRC and no previous personal diagnosis of the disease. Pooled screening participation levels were calculated for each screening modality. Seventeen studies, accounting for a total of 13,269 subjects with a family history of CRC met the inclusion criteria. Seven studies, including a total of 6,901 subjects had a pooled faecal occult blood testing screening participation (at least once) of 25 % (95 % CI 12–38). Five studies including a total of 5,091 subjects had a pooled sigmoidoscopy-based screening participation (at least once) of 16 % (95 % CI 7–27). Seven studies including a total of 9,965 subjects had pooled participation colonoscopy-based screening (at least once) of 40 % (95 % CI 26–54). There was a significant level of screening heterogeneity between studies. This review identified a substantial underuse of CRC screening for people at increased risk of developing the disease. It highlights the potential opportunity that exists for increasing screening participation among this segment of the population and the need to adjust the current CRC screening policies towards that objective.
Literature
1.
2.
3.
4.
Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA (2010) Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology 138(3):877–885PubMedCrossRef
5.
6.
7.
8.
Samowitz WS, Curtin K, Lin HH et al (2001) The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 121(4):830–838PubMedCrossRef
9.
10.
Macklin MT (1960) Inheritance of cancer of the stomach and large intestine in man. J Natl Cancer Inst 24:551–571PubMed
11.
St John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES (1993) Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 118(10):785–790PubMedCrossRef
12.
13.
14.
15.
16.
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement (2008). Ann Intern Med 149(9):627–637
17.
18.
Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58(3):130–160. doi:10.​3322/​CA.​2007.​0018 PubMedCrossRef
19.
20.
21.
22.
Liljegren A, Lindgren G, Brandberg Y et al (2004) Individuals with an increased risk of colorectal cancer: perceived benefits and psychological aspects of surveillance by means of regular colonoscopies. J Clin Oncol 22(9):1736–1742PubMedCrossRef
23.
24.
25.
Clavel-Chapelon F, Joseph R, Goulard H (1999) Surveillance behavior of women with a reported family history of colorectal cancer. Prev Med 28(2):174–178PubMedCrossRef
26.
Cockburn J, Paul C, Tzelepis F, McElduff P, Byles J (2002) Screening for bowel cancer among NSW adults with varying levels of risk: a community survey, 3 edn. The Cancer Council NSW Cancer Education Research Program, School of Medical Practice and Population Health, University of Newcastle, Wallsend, New South Wales. jillc@mail.newcastle.edu.au, pp 236–41
27.
Codori AM, Petersen GM, Miglioretti DL, Boyd P (2001) Health beliefs and endoscopic screening for colorectal cancer: potential for cancer prevention. Prev Med 33(2 Pt 1):128–136. doi:10.​1006/​pmed.​2001.​0862 PubMed
28.
Courtney RJ, Paul CL, Sanson-Fisher RW et al (2012) Colorectal cancer screening in Australia: a community-level perspective. Med J Aust 196(8):516–520PubMedCrossRef
29.
Eisinger F, Giordanella JP, Didelot R et al (1996) Screening practices and familial antecedents of colorectal cancer. Survey with a voluntary population. [French]. Gastroenterol Clin Biol 20(8–9):627–632PubMed
30.
Fletcher RH, Lobb R, Bauer MR et al (2007) Screening patients with a family history of colorectal cancer. J Gen Intern Med 22(4):508–513PubMedCrossRef
31.
Griffith KA, McGuire DB, Royak-Schaler R, Plowden KO, Steinberger EK (2008) Influence of family history and preventive health behaviors on colorectal cancer screening in African Americans. Cancer 113(2):276–285PubMedCrossRef
32.
Harris MA, Byles JE (1997) A survey of screening compliance among first degree relatives of people with colon cancer in New South Wales. J Med Screen 4(1):29–34PubMed
33.
Mack LA, Cook LS, Temple WJ, Carlson LE, Hilsden RJ, Paolucci EO (2009) Colorectal cancer screening among first-degree relatives of colorectal cancer patients: benefits and barriers. Ann Surg Oncol 16(8):2092–2100. doi:10.​1245/​s10434-009-0528-z PubMedCrossRef
34.
Madlensky L, Esplen MJ, Gallinger S, McLaughlin JR, Goel V (2003) Relatives of colorectal cancer patients: factors associated with screening behavior. Am J Prev Med 25(3):187–194PubMedCrossRef
35.
Manne S, Markowitz A, Winawer S et al (2002) Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol 21(1):3–15PubMedCrossRef
36.
Murff HJ, Peterson NB, Fowke JH et al (2008) Colonoscopy screening in African Americans and Whites with affected first-degree relatives. Arch Intern Med 168(6):625–631PubMedCrossRef
37.
Richardson JL, Danley K, Mondrus GT, Deapen D, Mack T (1995) Adherence to screening examinations for colorectal cancer after diagnosis in a first-degree relative. Prev Med 24(2):166–170PubMedCrossRef
38.
Shah M, Zhu K, Palmer RC, Jatoi I, Shriver C, Wu H (2007) Breast, colorectal, and skin cancer screening practices and family history of cancer in U.S. women. J Womens Health 16(4):526–534CrossRef
39.
Shah M, Zhu K, Palmer RC, Wu H (2007) Family history of cancer and utilization of prostate, colorectal and skin cancer screening tests in U.S. men. Prev Med 44(5):459–464PubMedCrossRef
40.
Thrasher JF, Cummings KM, Michalek AM, Mahoney MC, Moysich KB, Pillittere DM (2002) Colorectal cancer screening among individuals with and without a family history. J Publ Health Manag Pract JPHMP 8(2):1–9CrossRef
41.
42.
Ritvo P, Myers R, Del Giudice ME et al (2009) Fecal occult blood testing: people in Ontario are unaware of it and not ready for it. Can Fam Physician 55(2):176–177.e4PubMed
43.
44.
45.
46.
47.
Manne S, Markowitz A, Winawer S et al (2003) Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model, 1 edn. Prev Med An Int J Devot Pract Theory. Elsevier Science, Netherlands
48.
49.
50.
51.
Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF (2003) Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 139(12):959–965PubMedCrossRef
52.
Levitzky BE, Brown CC, Heeren TC, Schroy PC 3rd (2011) Performance of a risk index for advanced proximal colorectal neoplasia among a racially/ethnically diverse patient population (risk index for advanced proximal neoplasia). Am J Gastroenterol 106(6):1099–1106. doi:10.​1038/​ajg.​2011.​20 PubMedCrossRef
53.
54.
55.
Hopper JL (2005) Application of genetics to the prevention of colorectal cancer. Recent results in cancer research Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 166:17–33PubMed
56.
Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. doi:10.​1136/​bmj.​d4002 PubMedCrossRef
57.
Madlensky L, McLaughlin J, Goel V (2003) A comparison of self-reported colorectal cancer screening with medical records. Cancer Epidemiol Biomark Prev 12(7):656–659
Metadata
Title
Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis
Authors
Driss Ait Ouakrim
Trevor Lockett
Alex Boussioutas
John L. Hopper
Mark A. Jenkins
Publication date
01-09-2013
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2013
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9658-3

Other articles of this Issue 3/2013

Familial Cancer 3/2013 Go to the issue

Short Communication

Splice site mutations in mismatch repair genes and risk of cancer in the general population

Original Article

Detection of large deletions in the VHL gene using a Real-Time PCR with SYBR Green

Original Article

Mutation screening in a Norwegian cohort with pheochromocytoma

Original Article

Diagnosis and management of BHD-associated kidney cancer

OriginalPaper

Birt–Hogg–Dubé syndrome: from gene discovery to molecularly targeted therapies

Erratum

Erratum to: Birt–Hogg–Dubé: beyond the clinical manifestations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits